Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Renee P. Tannenbaum Acquires 10,000 Shares of Stock
Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Renee P. Tannenbaum Acquires 10,000 Shares of Stock
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) Director Renee P. Tannenbaum bought 10,000 shares of Cardiff Oncology stock in a transaction on Thursday, September 15th. The shares were acquired at an average price of $1.72 per share, for a total transaction of $17,200.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company's stock, valued at approximately $17,200. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.
卡迪夫肿瘤学公司(纳斯达克代码：CRDF-GET评级)董事在9月15日星期四的一笔交易中购买了10,000股卡迪夫肿瘤学股票。这些股票是以每股1.72美元的平均价格收购的，总交易额为17,200.00美元。收购完成后，董事现在拥有10,000股该公司股票，价值约17,200美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的，可以通过以下链接访问该文件。
Cardiff Oncology Stock Up 9.5 %
卡迪夫肿瘤学股票上涨9.5%
Cardiff Oncology stock opened at $1.73 on Tuesday. Cardiff Oncology, Inc. has a 12 month low of $1.13 and a 12 month high of $7.63. The stock's 50 day moving average is $2.51 and its 200-day moving average is $2.13.
周二，卡迪夫肿瘤学股票开盘报1.73美元。加的夫肿瘤学公司的股价为1.13美元的12个月低点和7.63美元的12个月高位。该股的50日移动均线切入位在2.51美元，200日移动均线切入位在2.13美元。
Cardiff Oncology (NASDAQ:CRDF – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.01. Cardiff Oncology had a negative return on equity of 28.82% and a negative net margin of 9,841.41%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million. Research analysts predict that Cardiff Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.
卡迪夫肿瘤学公司(纳斯达克代码：CRDF-GET Rating)最近一次公布收益结果是在8月4日星期四。该公司公布了本季度每股收益(0.24美元)，比普遍预期的(0.25美元)高出0.01美元。加的夫肿瘤公司的净资产回报率为负28.82%，净利润率为负9841.41%。该公司本季度营收为90万美元，而市场普遍预期为80万美元。研究分析师预测，卡迪夫肿瘤公司将公布本财年每股收益为1.04美元。
Institutional Investors Weigh In On Cardiff Oncology
机构投资者参与加的夫肿瘤学
Analysts Set New Price Targets
分析师设定新的价格目标
Several analysts recently issued reports on CRDF shares. Robert W. Baird dropped their target price on Cardiff Oncology from $9.00 to $6.00 and set an "outperform" rating on the stock in a report on Monday, August 29th. HC Wainwright dropped their target price on Cardiff Oncology from $22.00 to $14.00 and set a "buy" rating on the stock in a report on Friday. Finally, Piper Sandler lowered their price target on Cardiff Oncology from $7.00 to $5.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $9.75.
几位分析师最近发布了有关CRDF股票的报告。罗伯特·W·贝尔德在8月29日星期一的一份报告中将加的夫肿瘤公司的目标价从9.00美元下调至6.00美元，并对该股设定了“跑赢大盘”的评级。HC Wainwright在周五的一份报告中将加的夫肿瘤学的目标价从22.00美元下调至14.00美元，并对该股设定了“买入”评级。最后，派珀·桑德勒在9月13日(星期二)的一份研究报告中将他们对卡迪夫肿瘤学的目标价从7.00美元下调至5.00美元，并对该股设定了“增持”评级。根据MarketBeat的数据，五位分析师对该股的评级为买入，该公司目前的平均评级为“买入”，共识目标价为9.75美元。
Cardiff Oncology Company Profile
加的夫肿瘤学公司简介
(Get Rating)
(获取评级)
Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
加的夫肿瘤学公司是一家临床阶段的肿瘤学公司，在加利福尼亚州为癌症患者开发药物治疗。它的主要候选药物是onvansertib，一种用于抗癌治疗的口服选择性Polo-like Kinase 1抑制剂；CY140，一种PLK1、PLK2和PLK3的抑制剂，正处于实体肿瘤和白血病的1/2期研究；转移性结直肠癌，正在进行临床试验；以及trov-054，是FOLFIRI和贝伐单抗的1b/2期药物。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- 免费获取StockNews.com关于卡迪夫肿瘤学的研究报告(CRDF)
- 甲骨文的短期痛苦可能是你的长期收益
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它：投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗？
- 自动区重新进入拉力赛模式，新高在望
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受加的夫肿瘤学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对加的夫肿瘤学和相关公司的最新新闻和分析师评级的每日简要摘要。